KANSAS CITY SOUTHERN Form 8-K March 31, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of theSecurities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2014

Kansas City Southern

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction 1-4717 (Commission 44-0663509 (I.R.S. Employer

of incorporation)

File Number) 427 West 12th Street **Identification No.)**

Edgar Filing: KANSAS CITY SOUTHERN - Form 8-K

Kansas City, Missouri 64105

(Address of principal executive office)(Zip Code)

(816) 983-1303

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Kansas City Southern ("KCS") is furnishing under Item 7.01 of this Current Report on Form 8-K the information included as Exhibit 99.1 to this report. Exhibit 99.1 is the KCS news release dated March 25, 2014, announcing the date, time and other relevant information regarding KCS's presentation and conference call of its financial results for the quarter ended March 31, 2014.

Item 9.01 Financial Statements and Exhibits.

(d)

News Release issued by Kansas City Southern, dated March 25, 2014, entitled "KCS Announces First Quarter 2014 Earnings Release and Conference Call Time" is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

KANSAS CITY SOUTHERN

By: /s/ Adam J. Godderz Name: Adam J. Godderz Title: Corporate Secretary

Date: March 31, 2014

INDEX TO EXHIBITS

Number

Description

99.1 News Release issued by Kansas City Southern, dated March 25, 2014 entitled "KCS Announces First Quarter 2014 Earnings Release and Conference Call Time" is attached hereto as Exhibit 99.1.
es New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%"> Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

Rule 13e-4(i) (Cross-Border Issuer Tender Offer) Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) This Amendment No. 1 (this Amendment), which amends and supplements the Tender Offer Statement on Schedule TO (together with any subsequent amendments and supplements thereto, including this Amendment, the Schedule TO), is filed by Sanofi, a French *société anonyme* (Offeror). This Schedule TO relates to the offer by Offeror to purchase up to 100% of the issued and outstanding ordinary shares, no nominal value (Shares) of Ablynx NV, a Belgian *naamloze vennootschap* (the Company) from U.S. holders (within the meaning of Rule 14d-1(d) under the U.S. Securities Exchange Act of 1934, as amended (the Exchange Act)) and up to 100% of the outstanding Shares of the Company represented by American Depositary Shares of the Company (each, an ADS and collectively, ADSs) issued by JPMorgan Chase Bank, N.A., acting as depositary (the Depositary and all holders from time to time of American depositary receipts (ADRs) issued thereunder (as amended, the Deposit Agreement), from all holders, wherever located, at a price of 45.00 per Share and per ADS, net to the seller in cash, without interest (the Offer Price).

Capitalized terms used but not defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO.

This Amendment is being filed to amend and supplement Items 1 through 9 and Item 11.

Items 1 through 9 and Item 11.

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

The initial acceptance period of the U.S. Offer (and the related withdrawal rights) expired as scheduled on the Initial Expiration Date. As previously disclosed, Offeror will publish the results of the initial acceptance period of the U.S. Offer within five (5) Business Days, including whether or not Offeror will commence a Voluntary Subsequent Offering Period, the Mandatory Subsequent Offering Period or the Squeeze-Out period, as applicable. To the extent that the conditions to the Offers are satisfied, Offeror will pay for all Shares and ADSs that were validly tendered and not withdrawn within ten (10) Business Days following the publication of such results, in accordance with Belgian law.

SIGNATURES

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: May 7, 2018

Sanofi

By: /s/ Karen Linehan Name: Karen Linehan Title: Executive Vice President and General Counsel